Kris Wain, Mahesh Maiyani, Nikki M. Carroll, Rafael Meza, Robert T. Greenlee, Christine Neslund-Dudas, Michelle R. Odelberg, Caryn Oshiro, Debra P. Ritzwoller
{"title":"与肺癌筛查相关的按服务类型划分的医疗费用模式","authors":"Kris Wain, Mahesh Maiyani, Nikki M. Carroll, Rafael Meza, Robert T. Greenlee, Christine Neslund-Dudas, Michelle R. Odelberg, Caryn Oshiro, Debra P. Ritzwoller","doi":"arxiv-2409.06026","DOIUrl":null,"url":null,"abstract":"Introduction: Lung cancer screening (LCS) increases early-stage cancer\ndetection which may reduce cancer treatment costs. Little is known about how\nreceipt of LCS affects healthcare costs in real-world clinical settings. Methods: This retrospective study analyzed utilization and cost data from the\nPopulation-based Research to Optimize the Screening Process Lung Consortium. We\nincluded individuals who met age and smoking LCS eligibility criteria and were\nengaged within four healthcare systems between February 5, 2015, and December\n31, 2021. Generalized linear models estimated healthcare costs from the payer\nperspective during 12-months prior and 12-months post baseline LCS. We compared\nthese costs to eligible individuals who did not receive LCS. Sensitivity\nanalyses expanded our sample to age-eligible individuals with any smoking\nhistory noted in the electronic health record. Secondary analyses examined\ncosts among a sample diagnosed with lung cancer. We reported mean predicted\ncosts with average values for all other explanatory variables. Results: We identified 10,049 eligible individuals who received baseline LCS\nand 15,233 who did not receive baseline LCS. Receipt of baseline LCS was\nassociated with additional costs of $3,698 compared to individuals not\nreceiving LCS. Secondary analyses showed suggestive evidence that LCS prior to\ncancer diagnosis decreased healthcare costs compared to cancer diagnosed\nwithout screening. Conclusion: These findings suggest LCS increases healthcare costs in the year\nfollowing screening. However, LCS also improves early-stage cancer detection\nand may reduce treatment costs following diagnosis. These results can inform\nfuture simulation models to guide LCS recommendations, and aid health policy\ndecision makers on resource allocation.","PeriodicalId":501273,"journal":{"name":"arXiv - ECON - General Economics","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patterns of Medical Care Cost by Service Type Associated with Lung Cancer Screening\",\"authors\":\"Kris Wain, Mahesh Maiyani, Nikki M. Carroll, Rafael Meza, Robert T. Greenlee, Christine Neslund-Dudas, Michelle R. Odelberg, Caryn Oshiro, Debra P. Ritzwoller\",\"doi\":\"arxiv-2409.06026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Lung cancer screening (LCS) increases early-stage cancer\\ndetection which may reduce cancer treatment costs. Little is known about how\\nreceipt of LCS affects healthcare costs in real-world clinical settings. Methods: This retrospective study analyzed utilization and cost data from the\\nPopulation-based Research to Optimize the Screening Process Lung Consortium. We\\nincluded individuals who met age and smoking LCS eligibility criteria and were\\nengaged within four healthcare systems between February 5, 2015, and December\\n31, 2021. Generalized linear models estimated healthcare costs from the payer\\nperspective during 12-months prior and 12-months post baseline LCS. We compared\\nthese costs to eligible individuals who did not receive LCS. Sensitivity\\nanalyses expanded our sample to age-eligible individuals with any smoking\\nhistory noted in the electronic health record. Secondary analyses examined\\ncosts among a sample diagnosed with lung cancer. We reported mean predicted\\ncosts with average values for all other explanatory variables. Results: We identified 10,049 eligible individuals who received baseline LCS\\nand 15,233 who did not receive baseline LCS. Receipt of baseline LCS was\\nassociated with additional costs of $3,698 compared to individuals not\\nreceiving LCS. Secondary analyses showed suggestive evidence that LCS prior to\\ncancer diagnosis decreased healthcare costs compared to cancer diagnosed\\nwithout screening. Conclusion: These findings suggest LCS increases healthcare costs in the year\\nfollowing screening. However, LCS also improves early-stage cancer detection\\nand may reduce treatment costs following diagnosis. These results can inform\\nfuture simulation models to guide LCS recommendations, and aid health policy\\ndecision makers on resource allocation.\",\"PeriodicalId\":501273,\"journal\":{\"name\":\"arXiv - ECON - General Economics\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"arXiv - ECON - General Economics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/arxiv-2409.06026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - ECON - General Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2409.06026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Patterns of Medical Care Cost by Service Type Associated with Lung Cancer Screening
Introduction: Lung cancer screening (LCS) increases early-stage cancer
detection which may reduce cancer treatment costs. Little is known about how
receipt of LCS affects healthcare costs in real-world clinical settings. Methods: This retrospective study analyzed utilization and cost data from the
Population-based Research to Optimize the Screening Process Lung Consortium. We
included individuals who met age and smoking LCS eligibility criteria and were
engaged within four healthcare systems between February 5, 2015, and December
31, 2021. Generalized linear models estimated healthcare costs from the payer
perspective during 12-months prior and 12-months post baseline LCS. We compared
these costs to eligible individuals who did not receive LCS. Sensitivity
analyses expanded our sample to age-eligible individuals with any smoking
history noted in the electronic health record. Secondary analyses examined
costs among a sample diagnosed with lung cancer. We reported mean predicted
costs with average values for all other explanatory variables. Results: We identified 10,049 eligible individuals who received baseline LCS
and 15,233 who did not receive baseline LCS. Receipt of baseline LCS was
associated with additional costs of $3,698 compared to individuals not
receiving LCS. Secondary analyses showed suggestive evidence that LCS prior to
cancer diagnosis decreased healthcare costs compared to cancer diagnosed
without screening. Conclusion: These findings suggest LCS increases healthcare costs in the year
following screening. However, LCS also improves early-stage cancer detection
and may reduce treatment costs following diagnosis. These results can inform
future simulation models to guide LCS recommendations, and aid health policy
decision makers on resource allocation.